Pfizer reports positive psoriatic arthritis study data for Xeljanz

Pfizer has announced new clinical trial data that demonstrates the effectiveness of its drug Xeljanz in the treatment of psoriatic arthritis.

The company has reported data from the phase III OPAL Broaden and OPAL Beyond studies, which evaluated the efficacy and safety of Xeljanz in adult patients with active psoriatic arthritis who had an inadequate response to established therapies.

OPAL Broaden met its primary efficacy endpoint by showing a statistically significant improvement in response rates among patients who had failed to respond to treatment with conventional synthetic disease-modifying antirheumatic drugs, while OPAL Beyond showed similar benefits among individuals who could not benefit from anti-TNF therapy.

Michael Corbo, chief development officer for inflammation and immunology at Pfizer Global Product Development, said: "As the only JAK inhibitor being investigated in psoriatic arthritis, tofacitinib, if approved, would provide patients and healthcare professionals the first medicine in a new class to treat this disease."

Currently, Xeljanz has not been approved for use in this indication. To date, its performance has been studied in approximately 6,300 patients with moderate to severe rheumatoid arthritis.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.